Bioventus has agreed to a U.S. contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain.
DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
“We are pleased DUROLANE is among the preferred options available to both Aetna Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”
Bioventus has agreed to a U.S. contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain.
DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of...
Bioventus has agreed to a U.S. contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain.
DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
“We are pleased DUROLANE is among the preferred options available to both Aetna Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”
Copy to clipboard 
